4.6 Article

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Related references

Note: Only part of the references are listed.
Correction Hematology

Treatment of relapsed and refractory multiple myeloma (vol 101, pg 396, 2016)

Pieter Sonneveld et al.

HAEMATOLOGICA (2016)

Correction Hematology

Treatment of relapsed and refractory multiple myeloma (vol 101, pg 396, 2016)

Pieter Sonneveld et al.

HAEMATOLOGICA (2016)

Review Hematology

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

Lorenzo Falchi et al.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)

Review Hematology

Ibrutinib in Waldenstrom macroglobulinemia: latest evidence and clinical experience

Jorge J. Castillo et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)

Article Hematology

Promising therapies in multiple myeloma

Giada Bianchi et al.

BLOOD (2015)

Editorial Material Oncology

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Jacob P. Laubach et al.

CLINICAL CANCER RESEARCH (2015)

Article Medicine, General & Internal

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

J. A. Burger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Review Oncology

Current treatment landscape for relapsed and/or refractory multiple myeloma

Meletios A. Dimopoulos et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2015)

Article Hematology

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

Rakesh Bam et al.

AMERICAN JOURNAL OF HEMATOLOGY (2013)

Review Immunology

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

Joseph J. Buggy et al.

INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)

Article Multidisciplinary Sciences

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee A. Honigberg et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Article Oncology

Clinically relevant end points and new drug approvals for myeloma

K. C. Anderson et al.

LEUKEMIA (2008)

Article Chemistry, Medicinal

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

Zhengying Pan et al.

CHEMMEDCHEM (2007)

Article Oncology

International uniform response criteria for multiple myeloma

B. G. M. Durie et al.

LEUKEMIA (2006)

Article Biochemistry & Molecular Biology

Phospholipase C-γ2 couples Bruton's tyrosine kinase to the NF-κB signaling pathway in B lymphocytes

JB Petro et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2001)